ZBIO — Zenas BioPharma, Inc.
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Global Select
- Employees: 130
- Website: https://zenasbio.com
Latest SEC filings for ZBIO
- S-8 — 2026-09-11
- S-3ASR — 2026-09-11
- S-3ASR — 2026-09-11
- SCHEDULE 13G — 2026-09-08
- 3 — 2026-09-02
- SCHEDULE 13D/A — 2026-08-19
- SCHEDULE 13D/A — 2026-08-17
- 10-Q — 2026-08-13
- 8-K — 2026-08-13
- 10-Q — 2026-05-13
Latest ZBIO news
- — Wall Street Analysts Predict a 77.61% Upside in Zenas BioPharma, Inc. (ZBIO): Here's What You Should Know (Zacks Investment Research)
- — Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease (GlobeNewswire Inc.)
- — Zenas BioPharma to Host Virtual R&D Event (globenewswire.com)
- — Zenas BioPharma: Obexelimab Is Being Graded On The Wrong Curve (seekingalpha.com)
- — Zenas BioPharma, Inc. (ZBIO) Discusses Obexelimab Prelaunch Strategy and Commercial Opportunity in IgG4-Related Disease Transcript (seekingalpha.com)
Educational tool only — not investment advice.